Succeeder(SH:688338)2022-04-21 16:00Financial Performance - The proposed profit distribution plan for 2021 includes a cash dividend of RMB 2.5 per 10 shares, totaling RMB 20,412,000, which accounts for 20.96% of the net profit attributable to shareholders[5]. - The company has not yet achieved profitability since its listing[4]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 15% year-over-year growth[14]. - In 2021, the company's operating revenue reached ¥239,915,362.66, representing a year-on-year increase of 7.88% compared to ¥222,398,393.41 in 2020[22]. - The net profit attributable to shareholders increased by 40.73% to ¥97,368,830.48 in 2021, up from ¥69,188,424.17 in 2020[24]. - The net cash flow from operating activities increased by 48.65% to ¥107,423,198.26 in 2021, up from ¥72,266,743.41 in 2020[24]. - The company achieved operating revenue of ¥239,915,362.66, a year-on-year increase of 7.88%[33]. - The company reported a significant increase in cash inflows from sales and interest income, contributing to the rise in operating cash flow[24]. Risk Management - The company has detailed various operational risks in the report, urging investors to be cautious[4]. - The company has a comprehensive risk factor section in the report for investor reference[4]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a commitment to investors[6]. - The company faces risks related to technological iteration and the long R&D cycle of in vitro diagnostic products, which may impact its competitive position if not addressed[81]. - The company relies on foreign suppliers for key raw materials, which poses risks related to import dependency and supply chain stability[83]. - The company faces risks related to reliance on imported raw materials, which could impact production if supply chain disruptions occur[84]. - The company is exposed to potential price reductions due to stricter government regulations on medical device pricing[87]. Research and Development - Research and development expenses increased by 30%, totaling 150 million RMB, focusing on advanced technologies in the healthcare sector[14]. - The R&D expenditure as a percentage of operating revenue increased to 6.34% in 2021, up from 6.01% in 2020[23]. - The company has developed 15 core technologies and holds 29 patents, including 8 invention patents, demonstrating strong independent research and development capabilities[47]. - The company has established a core technology cluster covering instruments, reagents, and consumables, with five major technology categories including blood rheology measurement and coagulation diagnostic testing[52]. - The company is focusing on the integration of automation and motion control technologies in the development of platelet aggregation products for clinical diagnosis[53]. - The company is actively expanding its product offerings and improving its technology through ongoing research and development initiatives[66]. - The company has established a strong brand presence in the thrombus and hemostasis in vitro diagnostic market, with over 9,000 domestic terminal medical institution users[193]. Corporate Governance - The board of directors has confirmed the authenticity and completeness of the annual report[5]. - The company has not disclosed any special arrangements for corporate governance[7]. - The governance structure of the company aligns with the regulatory requirements set forth by the China Securities Regulatory Commission[128]. - The company has established a robust investor relations management system to enhance communication and transparency with investors[130]. - The board of directors is composed of members who strictly adhere to the company's articles of association and relevant laws, ensuring compliance and effective governance[129]. - The company has implemented strict information disclosure practices, ensuring timely and accurate communication with investors and regulatory bodies[130]. - The company has maintained independence from its controlling shareholder in business, personnel, assets, and financial matters, ensuring autonomous operational capability[131]. Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 25% market share within the next two years[14]. - International sales revenue grew by 68.09%, enhancing the company's brand influence in regions such as the Middle East, Asia, and South America[35]. - The company has established a nationwide marketing service network, covering 29 provinces and key cities, serving tertiary and secondary hospitals[79]. - The company aims to expand its production capacity through the construction of a new production base and the addition of equipment and personnel[124]. - The marketing strategy includes strengthening the domestic marketing network and targeting large public hospitals and third-party testing institutions[125]. Employee and Operational Management - The company has a structured training program for new employees to ensure quick integration into the team[196]. - The company has implemented a comprehensive training program, including onboarding, skills training, and knowledge sharing, to enhance employee capabilities[169]. - The company has achieved a 100% labor contract signing rate, ensuring compliance with labor laws and protecting employee rights[195]. - The company provides various employee benefits, including paid annual leave, communication subsidies, and travel insurance for employees frequently on business trips[196]. - The company has conducted various training programs in 2021, focusing on new employee onboarding, job skills, and business knowledge[195]. Environmental Responsibility - The company is committed to sustainable development, focusing on environmental protection and social responsibility while promoting green practices in its operations[179]. - The company has implemented appropriate measures for wastewater, noise, and solid waste treatment, ensuring compliance with environmental protection laws and regulations[186]. - The company has taken measures to reduce carbon emissions by improving production processes and conserving energy[190]. - The company has established environmental management standards and procedures, including waste disposal management and wastewater treatment[189]. Shareholder Information - The total number of shares held by directors, supervisors, and senior management at the end of the reporting period was 37,303,483, a decrease of 489,218 shares during the year[135]. - The company has a well-defined cash dividend distribution mechanism, with clear decision-making processes and protection for minority shareholders' rights[174]. - The company has established a long-term effective cash dividend policy to ensure continuity and stability in dividend distribution, protecting the rights of shareholders, especially minority investors[172]. - The company plans to distribute a cash dividend of RMB 2.50 per 10 shares, totaling RMB 20,412,000, which represents 20.96% of the net profit attributable to shareholders for 2021[173].